Today, the Centers for Disease Control and Prevention released interim guidance for the use of medication to prevent HIV infection among heterosexually-active women and men. Physicians considering the use of anti-HIV medication to prevent infection among uninfected heterosexuals at high risk should ensure that patients are confirmed to be uninfected prior to use and provided regular testing and other key prevention services. This strategy, called pre-exposure prophylaxis, or PrEP, may be used by HIV-uninfected individuals to reduce their risk of HIV infection by taking a daily dose of medications that are also used for treating HIV. When used consistently and in combination with other prevention methods, it may offer an additional means to prevent infection for some men and women at very high risk.
The guidance on the use of PrEP among heterosexually-active adults in the United States was published today in CDC’s Morbidity and Mortality Weekly Report. For more information, please see our press release, fact sheet or newsroom.